Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Cellectis SA ADR

Start price
Target price
Perf. (%)
€6.75
11.01.22
€8.00
11.01.23
-65.63%
07.10.22

Could be worthwhile Investment >10% per year
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€14.38
03.10.22
€7.00
03.10.23
-44.51%
06.10.22

Good culture
Probably not worthwhile Investment
Below average Management
No Innovation
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€10.76
30.09.22
-
30.09.23
39.41%
03.10.22

Risky Investment
Inovio Pharma

Start price
Target price
Perf. (%)
€1.88
20.09.22
€1.60
20.09.23
-7.46%
03.10.22

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Omeros Corp.

Start price
Target price
Perf. (%)
€7.20
02.10.21
-
02.10.22
-53.29%
03.10.22

Probably not worthwhile Investment
buy
Adaptimmune Therapeutics PLC ADR

Start price
Target price
Perf. (%)
€1.16
27.09.22
-
27.09.23
-4.31%
01.10.22

Risky Investment
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€17.43
18.09.22
-
18.09.23
-17.30%
01.10.22

Risky Investment
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.29
27.09.22
-
27.09.23
26.64%
01.10.22

Risky Investment
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€15.08
21.09.22
-
21.09.23
-4.44%
01.10.22

Risky Investment
Prothena Corp. plc

Start price
Target price
Perf. (%)
€54.86
28.09.22
-
28.09.23
12.14%
01.10.22

Risky Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€1.21
19.09.22
-
19.09.23
-12.19%
01.10.22

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€199.36
07.09.22
€300.00
31.12.24
36.69%
30.09.22

Could be very worthwhile Investment >20% year
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€199.36
07.09.22
€300.00
31.12.24
36.69%
30.09.22

Could be very worthwhile Investment >20% year
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€199.36
07.09.22
€300.00
31.12.24
36.69%
30.09.22

Could be very worthwhile Investment >20% year
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€16.65
20.09.22
€32.00
31.01.23
-17.72%
30.09.22

Could be very worthwhile Investment >20% year
buy
Nicox S.A.

Start price
Target price
Perf. (%)
€3.19
29.09.21
€3.80
29.09.22
-46.37%
30.09.22

Could be worthwhile Investment >10% per year
Apellis Pharmaceuticals

Start price
Target price
Perf. (%)
€64.19
07.09.22
€35.00
31.12.24
8.24%
29.09.22

Could be very worthwhile Investment >20% year
buy
BeiGene Ltd ADR

Start price
Target price
Perf. (%)
€312.00
28.09.21
-
28.09.22
-54.17%
28.09.22

buy
Acceleron Pharma Inc.

Start price
Target price
Perf. (%)
€158.00
28.09.21
-
28.09.22
0.63%
28.09.22

buy
Genfit S.A.

Start price
Target price
Perf. (%)
€3.36
26.09.21
-
26.09.22
14.15%
27.09.22

Could be worthwhile Investment >10% per year
buy
Lysogene SA

Start price
Target price
Perf. (%)
€2.29
24.09.21
€3.00
24.09.22
-73.87%
25.09.22

Could be worthwhile Investment >10% per year
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€213.80
18.01.22
€350.00
18.01.23
47.33%
23.09.22

Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
buy
Evotec SE

Start price
Target price
Perf. (%)
€43.60
21.09.21
-
21.09.22
-57.56%
21.09.22

buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.39
03.08.22
€2.80
03.08.23
-14.19%
20.09.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Inovio Pharma

Start price
Target price
Perf. (%)
€2.12
03.08.22
€2.60
03.08.23
-11.19%
20.09.22

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital